Espranor used in Moderate to Severe Pain: Sublingual/Buccal: Initial induction dose of 0.8–4 mg on day 1, adjusted to a usual maintenance dosage of 12–24 mg/day (max 32 mg/day).

Contraindication: Hypersensitivity to Espranor (Buprenorphine) or components of the formulation. Acute respiratory depression, comatose patients, head injury, raised intracranial pressure, and risk of paralytic ileus. Severe hepatic impairment Precaution: Respiratory and CNS Depression: May cause life-threatening respiratory depression, especially during initiation, dosage increases, or when combined with benzodiazepines or alcohol. Addiction, Abuse, and Misuse: Carries a risk of dependence and addiction, even at therapeutic doses. Taper slowly when discontinuing to avoid withdrawal. Opiate Withdrawal: As a partial agonist, buprenorphine can precipitate marked opiate withdrawal if administered to patients physically dependent on full opiate agonists before the agonist effects have subsided. QT-Interval Prolongation: Has the potential to prolong the QT interval; avoid in patients with a history of long QT syndrome or those taking class IA or III antiarrhythmics. Dental Complications: Transmucosal preparations are associated with adverse dental events (cavities, tooth decay, dental abscesses, tooth loss). Accidental Exposure: Accidental ingestion by children can cause fatal respiratory depression. Pregnancy: Opiates cross the placenta and may produce respiratory depression in neonates or lead to neonatal opiate withdrawal syndrome (NOWS) after prolonged maternal use. However, untreated opiate addiction carries significant risks to the mother and fetus. Guidelines generally recommend single-entity buprenorphine over the buprenorphine/naloxone combination during pregnancy to protect the fetus from naloxone exposure, though recent evidence suggests both may be safe. Breastfeeding: Espranor (Buprenorphine) is distributed into human milk in low concentrations. Women stable on buprenorphine for opiate dependence are generally encouraged to breastfeed to prevent relapse and potentially decrease the severity of neonatal opiate withdrawal. The infant should be closely monitored for drowsiness, difficulty breathing, adequate weight gain, and developmental milestones. (Note: Manufacturers of formulations labeled purely for pain often advise against breastfeeding. Renal/Hepatic Impairment: Hepatic Impairment: Espranor (Buprenorphine) is extensively metabolized by the liver. In severe hepatic impairment, avoid transdermal patches, extended-release injections, and implants. For sublingual tablets, the initial dose and titration increments should be reduced by half. Renal Impairment: Mild to moderate impairment generally requires no dose adjustment. Manufacturers advise caution in severe renal impairment, and dose reductions may be necessary for sublingual tablets.

Espranor contains Buprenorphine, a synthetic opiate partial agonist analgesic, primarily used for the relief of moderate to severe pain and as a substitution therapy in the management of opiate dependence.

Common: Sedation, drowsiness, dizziness, headache, nausea, vomiting, constipation, dry mouth, sweating, and application-site reactions (pruritus, erythema) for transdermal/implant/SC forms. Cardiovascular: Peripheral edema, hypertension, and potentially severe hypotension (including orthostatic hypotension and syncope). Hepatic: Cytolytic hepatitis, jaundice, and asymptomatic elevations in transaminases have been reported, particularly in OUD patients. Rare/Severe: Anaphylaxis, respiratory depression, seizures, and severe dental decay (from transmucosal forms).

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.